List view / Grid view
Many drugs fail in clinical trials due to toxicity-related issues; therefore, drug-mediated cellular toxicity should be determined at an early stage in the drug discovery value chain. There are many assay systems that can be utilised to measure cellular toxicity. In this article we demonstrate that intracellular ATP concentrations are…
This article compares and contrasts a commonly used cell viability assay in manual and automated fashion and provides exemplar data from each scenario.
The screening of drug targets against compound libraries is now a mature and validated approach to identifying the chemical starting points of drugs...
Drug resistance is a significant therapeutic problem, from infectious diseases to cancer. Given a large enough population of genetically varying target cells, the emergence of drug resistance is not surprising and is even unavoidable...
In this application note, Sheraz Gul (Fraunhofer-IME SP), Markus Wolf (Fraunhofer-IME SP), Enda O’Connell (National University of Ireland Galway) and Howard Fearnhead (National University of Ireland Galway), demonstrate that the Echo 550 Liquid Handler can precisely and accurately transfer nanolitre volumes of compound with acoustic energy in a completely contact-free…
Featured in this Stem Cells In-depth Focus: Translating stem cell biology into drug discovery; Mechanism-informed phenotypic screening – the missing link for cancer drug discovery; Analysis of human stem cell interactions at the single-cell resolution...
Cancer cells exhibit huge phenotypic diversity, with many well-defined phenotypes, such as invasion, deregulated proliferation and immune evasion, contributing to disease outcomes, making them uniquely amenable to phenotypic screening1...
Alzheimer’s disease (AD) is the most common form of dementia which typically occurs after the age of 65 and is characterised by progressive cognitive impairment...
High throughput screening (HTS) continues to be employed in drug discovery as the primary source of identifying chemical starting points for drug discovery and tool compounds for chemical biology, respectively. Although small molecule drug discovery efforts have focused largely upon enzyme, receptor and ion-channel targets, there has been an increase…
Preview of the upcoming foreword in our April issue, written by Sheraz Gul, Vice President and Head of Biology at Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, Germany...
Sheraz Gul, Head of Biology at Fraunhofer-IME SP, provides an in-depth review of the Cell-Based Assays for Screening workshop which took place in December 2014...
Despite the ever increasing efforts being expended for drug discovery purposes, the number of approved drugs remains relatively static. A variety of explanations have been provided to explain this observation and initiatives to remedy this situation have been implemented. Many of these initiatives are still works-in-progress and whether these will…
